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Optimistic, Realistic, and Pessimistic Illness Perceptions; 
Quality of Life; and Survival Among 2457 Cancer Survivors: 
The Population-Based PROFILES Registry
Belle H. de Rooij, MSc1,2 ; Melissa S.Y. Thong, PhD3; Janneke van Roij, MSc2; Cynthia S. Bonhof, MSc2;  
Olga Husson, PhD4; and Nicole P.M. Ezendam, PhD1,2
BACKGROUND: Threatening illness perceptions (IPs) have been associated with poorer health outcomes. However, to the authors' 
knowledge, it remains unclear whether threatening IPs that are consistent with disease severity are equally harmful. The aim of the 
current study was to: 1) identify subgroups of cancer survivors based on IPs and prognosis; and 2) assess the health-related quality 
of life (HRQOL) and survival associated with these subgroups. METHODS: The authors used survey data from the population-based 
Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship (PROFILES) registry, which were 
collected between 2008 and 2015 and included 2457 cancer survivors who were <5 years after their cancer diagnosis (colon, rectal, 
prostate, endometrial, or ovarian cancer or non-Hodgkin lymphoma). Clinical and survival data were collected through the 
Netherlands Cancer Registry. Subgroups were defined by IPs (Brief Illness Perception Questionnaire) and prognosis (conditional 
5-year relative survival) into survivors with 1) IPs consistent with prognosis (“realistic”); 2)  less threatening IPs than expected based 
on prognosis (“optimistic”); and 3) more threatening IPs than expected based on prognosis (“pessimistic”). RESULTS: Compared 
with survivors with realistic IPs (1230 survivors), those with optimistic IPs (582 survivors) were found to have a higher HRQOL (P < .01 
on all European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 [EORTC QLQ-C30] 
scales) and a lower all-cause mortality (hazard ratio, 0.72; P < .01), whereas those with pessimistic IPs (645 survivors) had a lower 
HRQOL (P < .01 on all scales) and a higher all-cause mortality (hazard ratio, 1.52; P < .01). CONCLUSIONS: Optimistic IPs are associ-
ated with better HRQOL and survival, even if they may appear to be unrealistic with respect to cancer survivors' prognosis. Survivors 
with pessimistic IPs appear to have the worst outcomes. Therefore, efforts are needed to provide better support to patients with 
pessimistic IPs to improve their outcomes. Cancer 2018;124:3609-17. © 2018 The Authors. Cancer published by Wiley Periodicals, 
Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution-
NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, 
the use is non-commercial and no modifications or adaptations are made.
KEYWORDS: cancer survivors, health-related quality of life (HRQOL), illness perceptions (IPs), prognosis, survival.
INTRODUCTION
The illness perceptions (IPs) of patients, comprising both cognitive and emotional responses to their illness, are increas-
ingly being studied in relation to physical and psychological outcomes.1 Threatening IPs, such as concern regarding 
the disease and the number of symptoms experienced, have been associated with poor health-related quality of life 
(HRQOL), psychological morbidities, and low survival among cancer survivors.2‒10 These findings suggest that having 
threatening IPs affects survivors' outcomes. However, IPs may accurately reflect a patient's true disease status, indicating 
that the associations between IPs and outcomes largely are explained by disease severity (ie, prognosis).4 Conversely, 
patients also could hold more optimistic or pessimistic beliefs regarding their disease that are not consistent with disease 
severity or prognosis.
The IPs of cancer survivors may become more concordant with disease severity or prognosis when these individuals 
receive explicit information regarding the diagnosis, side effects, and prognosis of their cancer.11‒13 In patients with can-
cer who are receiving palliative care, realistic perceptions of prognosis may contribute to acceptance of the disease and its 
consequences, without the patients being disappointed with or frustrated by unachievable expectations.14‒16 However, to 
the best of our knowledge, the advantages of realistic IPs among cancer survivors remain unclear. Efforts to investigate 
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the benefits of realistic, pessimistic, or optimistic IPs rel-
ative to prognosis among cancer survivors may provide 
insights into survivors' perspectives, and may provide 
information with which to guide information provision 
and support to those at risk of physical and emotional 
symptoms.
In a large observational cohort of cancer survivors 
with various cancer diagnoses, we sought to identify 
subgroups of survivors with realistic, pessimistic, or op-
timistic IPs relative to prognosis at the time of the ques-
tionnaire. In addition, we aimed to assess the HRQOL 
and survival associated with these subgroups. In parallel 
with literature demonstrating the benefits of prognostic 
awareness in patients receiving palliative care,14,15 we hy-
pothesized that realistic IPs among cancer survivors are 
associated with better outcomes compared with either 
optimistic or pessimistic IPs.
MATERIALS AND METHODS
Design/Setting
We used data from the Patient Reported Outcomes 
Following Initial treatment and Long term Evaluation 
of Survivorship (PROFILES) registry.17 Patient-reported 
outcomes are collected within a sampling frame of the 
Netherlands Cancer Registry (NCR) and can be linked 
with clinical data from all individuals newly diagnosed 
with cancer in the Netherlands.
Data Collection
A detailed description of the data collection has been pre-
sented previously.17 In brief, in each study sample, cancer 
survivors were informed about the study via a letter from 
their attending specialist. This letter contained either 
an informed consent form and a paper questionnaire or 
a secured link to a Web-based informed consent form 
and online questionnaire. In study samples in which the 
secured link was provided, the patient could return a 
postcard to request a paper-and-pencil questionnaire if 
preferred. Data from the PROFILES registry are freely 
available for noncommercial scientific research, subject 
to study question, privacy and confidentiality restric-
tions, and registration (www.profileregistry.nl).
Study Population
The current analysis included 5 study samples from the 
PROFILES registry for which data were available regard-
ing dependent and independent variables. Only short-
term cancer survivors (<5 years after diagnosis) were 
included, because, among long-term cancer survivors, the 
IPs may be less likely to be related to the cancer diagnosis 
and more likely the consequence of comorbid conditions. 
Cancer types included colon, rectal, prostate, endometrial, 
and ovarian cancer as well as non-Hodgkin lymphoma. In 
all study samples, a core set of the same questionnaires 
was used, with inclusion between May 2009 and March 
2014. Participants were excluded if they were not able to 
complete a Dutch questionnaire according to their (ex-)at-
tending specialist (ie, due to cognitive impairment, being 
a non-native speaker, being too ill to participate). Also ex-
cluded were individuals who died or emigrated before the 
initiation of the study, according to data from the hospital 
of diagnosis and/or data from the Dutch municipal per-
sonal records database (ie, mortality and residential data 
from all citizens through municipal registries). Ethical ap-
proval was obtained for all study samples separately from 
a local certified medical ethics committee.
Measures
Clinical data, such as the date of diagnosis, tumor type, 
tumor stage, and primary treatments received were ob-
tained from the NCR. The NCR routinely collects data 
concerning newly diagnosed patients with cancer in all 
hospitals in the Netherlands. Tumor type was classified 
according to the International Classification of Diseases for 
Oncology, 3rd Edition (ICD-O-3),18 and cancer stage was 
classified according to the TNM19 or Ann Arbor (Non-
Hodgkin lymphoma) staging system. Primary treatments 
received were classified as surgery, systemic therapy 
(chemotherapy, targeted therapy, or immune therapy), 
radiotherapy (including brachytherapy), hormone ther-
apy, no treatment/active surveillance, or unknown. The 
time from diagnosis at the time of questionnaire invita-
tion was categorized into quartiles (0-2 years, 2-3 years, 
3-5 years, and >5 years). Sociodemographic information 
(ie, educational level, marital status, employment sta-
tus, and comorbidity) was assessed in the questionnaire. 
Marital status (“married/living together” vs “divorced/
widowed/never married”) and employment status (“hav-
ing a paid job” vs “not having a paid job”) were dichot-
omized. Comorbidity was assessed using the adapted 
Self-Administered Comorbidity Questionnaire and 
categorized into no comorbidities, 1 comorbidity, or > 1 
comorbidities.20 Comorbidities included heart disease, 
stroke, hypertension, airway disease (asthma, chronic 
bronchitis, or chronic obstructive pulmonary disease), 
diabetes, stomach disease, kidney disease, liver disease, 
anemia or other blood disease, thyroid disease, depres-
sion, arthrosis, back pain, and rheumatic disease.
The Brief Illness Perception Questionnaire (BIPQ) 
was used to assess IPs.21 The BIPQ includes 8 items. 
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Test-retest reliability (Pearson correlations, 0.42-0.75) of 
the items is reported to be fair.21 Similar to earlier stud-
ies,22‒25 a 2-factor structure was found using principal 
components factor analysis. A multi-item scale was com-
puted of 5 BIPQ items selected through the factor anal-
ysis (factor loadings > 0.70), and included consequences 
(“How much does your illness affect your life?”), timeline 
(“How long do you think your illness will continue?”), 
identity (“How much do you experience symptoms from 
your illness?”), concern (“How concerned are you about 
your illness?”), and emotional response (“How much 
does your illness affect you emotionally?”). A multi-item 
scale was computed of these items by averaging the item 
scores, when ≤1 item response was missing. The internal 
validity of the scale was good (standardized Cronbach 
alpha,.85). Higher scores indicated more threatening IPs.
Prognosis at the time of the questionnaire was de-
termined by conditional 5-year relative survival (ie, the 
probability of surviving an additional 5 years on the con-
dition that the patient has survived x number of years 
after diagnosis). Estimates were calculated using data 
from the NCR, including mortality data from patients 
diagnosed between 1989 and 2008 who were followed 
for up to 15 years, and were determined by years survived 
after diagnosi s, tumor type, tumor stage, age group (ages 
15-44 years, ages 45-59 years, ages 60-74 years, and ages 
75-89 years), and sex. Conditional relative survival data 
from the NCR has been described previously for colorec-
tal26 and prostate27 cancer as well as for non-Hodgkin 
lymphoma.28 For survivors of endometrial and ovarian 
cancer in the current study sample who were included 
within 1 year after diagnosis, the 5-year survival at the 
time of diagnosis by cancer stage was determined (www.
cijfersoverkanker.nl).
To create the optimistic, realistic, and pessimis-
tic IPs groups, the sample was divided into conditional 
5-year relative survival strata (<60%, 60%-69%, 70%-
79%, 80%-89%, and 90%-100%). Then, in each stra-
tum, quartiles of BIPQ multi-item scores were defined. 
Survivors with the lowest quartile of BIPQ scores in their 
stratum (<25%) were allocated to “pessimistic” IPs, those 
with interquartile scores (25%-75%) were allocated to 
“realistic” IPs, and those with the highest quartile (>75%) 
were allocated to “optimistic” IPs (Table 1).
The European Organization for the Research and 
Treatment of Cancer Quality of Life Questionnaire Core 
30  (EORTC QLQ-C30; version 3.0) was used to as-
sess HRQOL among the participants.29 The scores were 
linearly transformed into a score between 0 and 100.30 
Higher scores on the functioning scales indicated better 
functioning and global QOL, whereas higher scores on 
the symptom scales indicated more symptom complaints 
and financial difficulties. Vital status and date of death 
data were obtained from the Dutch municipal personal 
records database and last were verified on February 1, 
2017. Anxiety and depression were measured in survivors 
of colon cancer, rectal cancer, and lymphoma using the 
Hospital Anxiety and Depression Scale (HADS).31 The 
HADS assesses separate anxiety and depression scales, 
both of which consist of 7 items. Higher scores indicate 
more anxiety and depressive symptoms.
Statistical Analysis
Statistical analyses were conducted using SAS statisti-
cal software (version 9.4; SAS Institute Inc, Cary, North 
Carolina). Frequencies with percentages and means with 
standard deviations were used to describe the baseline 
characteristics, and chi-square tests, independent Student 
TABLE 1. Group Allocation of Survivors Into Optimistic, Realistic, and Pessimistic IPs Within 5-Year 
Conditional Survival Strata
Quartiles of IPs Scoresa
Prognosis at time of questionnaire 
(conditional 5-y relative survivalb) No. Total=2457
<25th: Optimistic 
N=582
25th-75th: Realistic 
N=1230
>75th: Pessimistic 
N=645
<60% 148 <4.4 4.4-7.3 >7.3
60%-69% 234 <2.4 2.4-6.2 >6.2
70%-79% 384 <2.4 2.4-5.8 >5.8
80%-89% 806 <2.6 2.6-6.0 >6.0
90%-100% 885 <2.0 2.0-5.2 >5.2
Abbreviation: IPs, illness perceptions.
aThe IPs score was based on the average of Brief Illness Perception Questionnaire (BIPQ) scores (1-10) of items selected in factor analysis (consequences, 
timeline, identity, concern, and emotional response). A higher score indicates a more threatening IPs.
bThe probability of surviving an additional 5 years on the condition that the patient has survived x number of years after diagnosis, based on years survived 
from diagnosis, tumor type, tumor stage, age group, and sex.
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t tests, and Mann-Whitney U tests were used to test the 
differences between patients with optimistic, realistic, 
and pessimistic IPs. P values < .05 were considered to be 
statistically significant.
Correlations were computed to assess whether BIPQ 
items were interrelated with HRQOL scales. General 
linear models were conducted to assess differences in 
HRQOL between survivors with optimistic, realistic, 
and pessimistic IPs. Bonferroni-corrected pairwise com-
parisons were made to compare survivors with optimistic 
versus realistic IPs and pessimistic versus realistic IPs, 
adjusted for a priori selected covariates (age at the time 
of the questionnaire, sex, educational level, years from 
diagnosis, tumor type, tumor stage, treatment [surgery, 
radiotherapy, or systemic therapy], number of comorbid-
ities, employment, and marital status). Additional analy-
ses were adjusted for anxiety and depression.
Kaplan-Meier curves were conducted to show dif-
ferences in survival between the 3 subgroups. A Cox 
proportional hazards regression model was performed to 
assess differences in survival between patients with op-
timistic, realistic, and pessimistic IPs. The survival du-
ration was specified as the time from the questionnaire 
until either death or the censoring date (February 1, 
2017). To adjust for survivorship bias, a variable with the 
left truncation time (time between diagnosis and ques-
tionnaire) was added as an argument and the time of the 
questionnaire was set as the entry time. In addition, the 
model was adjusted for covariates controlling for factors 
influencing survival (age at the time of the questionnaire, 
sex, educational level, tumor type, tumor stage, treatment 
[surgery, radiotherapy, or systemic therapy], number of 
comorbidities, employment, and marital status).
RESULTS
A total of 3882 cancer survivors were invited to partici-
pate in 1 of the 5 studies, 2744 of whom (71%) returned 
the questionnaire. The current analysis included 2457 
cancer survivors (63%) for whom no data were missing re-
garding the grouping variable (tumor stage to determine 
prognosis, BIPQ scale) (see Supporting Fig. 1). Cancer 
survivors were classified into those with optimistic (582 
survivors), realistic (1230 survivors), and pessimistic (645 
survivors) IPs (Table 1).
Compared with survivors with realistic IPs, those 
with optimistic IPs tended to be older, were more often 
male, were more often survivors of colon cancer and less 
often survivors of rectal and ovarian cancer, had lower 
stages of disease, had fewer comorbidities, and were less 
often employed. Survivors with pessimistic IPs tended to 
be younger, were more often female, were more often less 
educated, were less often survivors of colon cancer and 
more often survivors of rectal cancer, had more comor-
bidities, less often had a partner, and more often received 
radiotherapy (Table 2).
Correlations between BIPQ items that were in-
cluded in the IPs scale were weak to moderate (correla-
tion coefficient, -0.53 to 0.45) (see Supporting Table 1). 
For all HRQOL scales, functioning and global QOL 
were higher and symptom burden was lower in those 
with an optimistic IPs compared with those with a re-
alistic IPs (all P < .01). According to guidelines for clin-
ical relevance, mean differences were trivial or small.32 
Functioning was lower and symptoms were higher in 
those with pessimistic IPs compared with those with a 
realistic IPs (all P < .01), and mean differences were triv-
ial to large (Table 3).32 Differences remained significant 
after additional adjustment for anxiety and depression, 
and when analyses were stratified by prognosis group.
Overall, all-cause mortality was found to be higher 
in survivors with a pessimistic IPs compared with those 
with realistic IPs (adjusted hazard ratio, 1.52; 95% confi-
dence interval, 1.27-1.84 [P < .01]). In addition, all-cause 
mortality was found to be slightly but significantly lower 
in survivors with optimistic IPs compared with those 
with a realistic IPs (adjusted hazard ratio, 0.72; 95% con-
fidence interval, 0.57-0.90 [P < .05]) (Table 4) (Fig. 1).
DISCUSSION
We demonstrated that having optimistic IPs, even when 
they may appear unrealistic with respect to prognosis, 
are associated with higher HRQOL and lower mortality, 
whereas having pessimistic IPs is associated with poorer 
outcomes compared with IPs that are consistent with 
disease severity (ie, realistic IPs). This violates our hy-
pothesis that realistic IPs are more beneficial than more 
optimistic IPs, and demonstrates that IPs are important 
predictors of survivors' health outcomes regardless of dis-
ease prognosis. In addition, the comparison of the 3 IPs 
groups in the current study elucidated that differences in 
outcomes were much larger between the pessimistic IPs 
group and the realistic IPs group compared with between 
the optimistic and realistic IPs groups, specifically with 
respect to social functioning, cognitive functioning, fa-
tigue, nausea, insomnia, and global QOL.
Similar to previous work focusing on the relation-
ship between IPs and physical and psychological out-
comes, including HRQOL, psychological distress, and 
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mortality,2‒10 we found that less threatening (ie, more 
positive) IPs were associated with more favorable out-
comes, whereas more threatening (ie, more negative) IPs 
were associated with unfavorable outcomes. The results 
of the current study demonstrate that IPs are associated 
with HRQOL and survival independent of disease sever-
ity (ie,prognosis). According to the common sense model 
of self-regulation of Leventhal et al, the relationship 
between IPs and health outcomes is mediated through 
coping.33 Accordingly, threatening IPs have been associ-
ated with passive coping strategies, such as anxious pre-
occupation and helplessness/hopelessness among cancer 
survivors,4 which may explain the relation to poor health 
outcomes. An alternative explanation may be that the IPs 
in the current study simply were a more inclusive reflec-
tion of disease severity, comprising symptoms, disease 
progression, and comorbidities. This is in parallel with 
self-rated health as an inclusive measure of health sta-
tus, reflecting bodily sensations or symptoms indicating 
physiological dysregulations or preclinical disease,34,35 as 
well as internal or external resources that affect health (ie, 
educational level, financial status and social support, op-
timism, or self-control).36 Inclusiveness also may explain 
why IPs in the current study appeared to be predictive 
TABLE 2. Sociodemographic and Clinical Characteristics of Survivors With Optimistic, Realistic, or 
Pessimistic IPs
Total 
N=2457
Optimistic 
IPs N=582
Realistic 
IPs N=1230
Pessimistic 
IPs N=645
P for Optimistic 
Versus Realistica
P for Pessimistic 
Versus Realistica
Age at survey. y
Mean (SD) 68.1 (10.1) 69.3 (9.5) 68.3 (10.3) 66.7 (10.2) .03 <.01
Sex, no. (%)
Male 1457 (59) 380 (65) 730 (59) 347 (54) .02 .02
Female 1000 (41) 202 (35) 500 (41) 298 (46)
Education, no. (%)
Lower education 420 (17) 91 (22) 200 (48) 129 (20) .63 .03
Secondary education (high school) 684 (28) 153 (22) 341 (28) 190 (30)
Secondary education (vocational) 823 (34) 195 (34) 412 (34) 216 (34)
Higher education (vocational or 
university)
504 (21) 139 (28) 260 (52) 105 (16)
Y from diagnosis
Median (IQR) 2.7 (1.9-3.6) 2.8 (2.0-3.7) 2.7 (1.9-3.6) 2.6 (1.9-3.6) .40 .60
<2 680 (17) 150 (26) 345 (28) 185 (29) .42 .86
2-3 809 (21) 190 (33) 411 (33) 208 (32)
3-4 968 (25) 242 (42) 474 (39) 252 (26)
Cancer type, no. (%)
Colon 779 (32) 239 (41) 356 (46) 184 (24) <.01 <.01
Rectal 449 (18) 79 (14) 227 (18) 143 (22)
Prostate 516 (21) 107 (18) 297 (24) 112 (17)
Ovarian 142 (6) 16 (3) 79 (6) 47 (7)
Endometrial 197 (8) 42 (7) 112 (9) 43 (7)
Non-Hodgkin lymphoma (aggressive) 228 (9) 78 (13) 87 (7) 63 (28)
Non-Hodgkin lymphoma (indolent) 146 (6) 21 (4) 72 (76) 53 (8)
Comorbidities, no. (%)
None 742 (30) 215 (37) 381 (31) 146 (23) <.01 <.01
1 714 (29) 182 (31) 361 (29) 171 (27)
≥2 1001 (41) 185 (18) 488 (40) 328 (51)
Marital status, no. (%)
Partner 1949 (80) 456 (79) 992 (81) 501 (78) .28 .10
No partner 484 (20) 119 (21) 226 (19) 139 (29)
Employed, no. (%)
Yes 444 (19) 94 (17) 238 (120) 112 (18) .09 .28
No 1939 (81) 473 (83) 952 (80) 514 (82)
TNM/Ann Arbor stage of disease, no. (%)
I 627 (25) 154 (25) 317 (26) 156 (24) .01 .18
II 931 (38) 243 (42) 449 (37) 239 (37)
III 683 (28) 157 (27) 355 (29) 171 (27)
IV 195 (8) 23 (4) 99 (8) 73 (37)
Treatment, no. (%)
Surgery 1696 (69) 412 (71) 845 (69) 439 (68) .37 .78
Radiotherapy 688 (28) 138 (20) 338 (27) 212 (31) .09 .01
Systemic therapy 818 (33) 183 (31) 406 (33) 229 (36) .51 .28
Abbreviations: IPs, illness perceptions; IQR, interquartile range; SD, standard deviation.
Percentages do not always add up to 100 because they were rounded off to whole numbers.
aBold type indicates statistical significance  (P < 0.05).
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of health outcomes independent of prognosis, reflecting 
that all groups in the current study were rather “realistic” 
about their outcomes.
Consistent with literature regarding threatening 
IPs, pessimistic IPs were found to be associated with so-
ciodemographic factors, including younger age, being 
female, and having a low educational level.37,38 In ad-
dition, we found that higher cancer stage and more co-
morbidities were associated with having pessimistic IPs. 
Furthermore, survivors with pessimistic IPs more often 
received radiotherapy, which previously has been asso-
ciated with higher levels of psychological distress,39 fa-
tigue,40 and a lower HRQOL.
Limitations
Using comprehensive historical cancer registry data to 
estimate prognosis at the time of the questionnaire, we 
tried to adjust for the (clinical) factors that interfere with 
IPs and health outcomes (ie, years from diagnosis, can-
cer stage at the time of diagnosis, patient age and sex). 
However, other factors comprising prognosis were not 
covered in this estimate, such as comorbidities, disease 
progression, or disease recurrence. For example, the high 
prevalence of comorbidities in the group with a pessimis-
tic IPs may explain their low survival. Although adjust-
ment for comorbidities at the time of the questionnaire 
did not alter the current study results, we could not adjust 
TABLE 3. General Linear Models Comparing HRQOL and Symptoms Between Cancer Survivors With 
Optimistic, Realistic, and Pessimistic IPs Shown as Crude Means and SDs
Total 
N=2457
Optimistic IPs 
N=582
Realistic IPs 
N=1230
Pessimistic IPs 
N=645
P for Optimistic 
Versus Realistic 
(Size of 
Difference)a
P for Pessimistic 
Versus Realistic 
(Size of 
Difference)a
Global QOL 75.0 (19) 85.2 (14) 77.1 (16) 61.9 (22) <.01 (S) <.01 (L)
Functioning scales
Physical functioning 80.5 (20) 88.0 (15) 82.4 (18) 70.1 (23) <.01 (S) <.01 (S)
Social functioning 85.0 (23) 95.5 (12) 88.0 (19) 70.0 (29) <.01 (S) <.01 (L)
Cognitive functioning 83.7 (21) 90.2 (15) 85.1 (19) 75.2 (26) <.01 (S) <.01 (M)
Emotional functioning 84.4 (20) 94.4 (11) 87.4 (17) 69.9 (24) <.01 <.01
Role functioning 77.8 (28) 89.8 (19) 80.2 (25) 62.4 (33) <.01 (S) <.01 (S)
Symptom scales
Fatigue 25.1 (25) 13.4 (17) 23.0 (22) 40.0 (27) <.01 (S) <.01 (M)
Nausea/vomiting 4.4 (13) 1.7 (7) 3.4 (11) 8.5 (18) <.01 (T) <.01 (S)
Pain 17.5 (25) 9.5 (18) 15.7 (23) 28.3 (30) <.01 (S) <.01 (S)
Dyspnea 15.3 (25) 8.2 (19) 13.4 (23) 25.4 (31) <.01 (S) <.01 (M)
Insomnia 21.8 (30) 11.7 (22) 20.3 (28) 33.6 (34) <.01 (S) <.01 (M)
Appetite loss 6.8 (18) 2.7 (11) 5.3 (16) 13.5 (25) <.01 (T) <.01 (S)
Constipation 9.4 (21) 5.2 (15) 9.3 (20) 13.3 (25) <.01 (T) <.01 (T)
Diarrhea 9.6 (21) 5.0 (14) 9.2 (20) 14.1 (26) <.01 (S) <.01 (S)
Financial problems 7.2 (19) 2.7 (11) 5.4 (16) 14.7 (26) <.01 (T) <.01 (S)
Abbreviations: HRQOL, health-related quality of life; IPs, illness perceptions; L, large difference, M, medium difference; S, small difference; SD, standard 
deviation; T, trivial difference.
aAnalyses were adjusted for age at the time of the survey, sex, educational level, years from diagnosis, tumor type, tumor stage, treatment (surgery, radio-
therapy, or systemic therapy), number of comorbidities, employment, and marital status. Higher scores on global QOL and functioning scales and lower 
scores on symptom scales indicate a better HRQOL. The size of the mean difference was determined based on guidelines of clinical relevance from Cocks 
et al.32 The guideline for the emotional functioning subscale is unknown.
TABLE 4. Cox Proportional Hazards Regression Models for Optimistic Versus Realistic IPs and Pessimistic 
Versus Realistic IPs
No. No. of Person-Years Deaths Unadjusted HR (95% CI)a Adjusted HR (95% CI)a,b
Total
Realistic IPs 582 6194.4 288 1.00 (referent) 1.00 (referent)
Optimistic IPs 1230 3159.4 106 0.74 (0.58-0.91)c 0.72 (0.57-0.90)c
Pessimistic IPs 645 3065.2 218 1.52 (1.28-1.81)d 1.52 (1.27-1.84)d
Abbreviations: 95% CI, 95% confidence interval; HR, hazard ratio; IPs, illness perceptions.
aBold type indicates statistical significance.
bAdjusted for age at the time of the survey, sex, educational level, tumor type, tumor stage, treatment (surgery, radiotherapy, or systemic therapy), number 
of comorbidities, employment, and marital status.
cP < .01.
dP<.05.
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for comorbidities at the time of diagnosis or in the years 
after questionnaire completion. In addition, no data 
were available regarding disease progression or recur-
rence. The inclusion of survivors with recurrent disease 
may have inflated the results of the current study because 
these individuals were likely allocated to the pessimistic 
IPs group and inevitably had poorer health outcomes.
Furthermore, our composite BIPQ scale was based 
on a factor structure that was similar to that of other 
studies,22‒25 but does not support the theoretical model 
by Leventhal et al that presents emotional and cognitive 
representations as distinct factors.33 As a consequence, 
the groups in the current study were not only based on 
cognitive perceptions regarding disease severity, such as 
perceptions of how long the disease will continue, but 
also on emotional representations. Therefore, it is not 
surprising that the groups were strongly associated with 
HRQOL subscales. To further elucidate whether more 
optimistic perceptions of prognosis are indeed more 
beneficial for cancer survivors than (clinically) accurate 
perceptions of prognosis, a prognostic awareness measure 
could be used to create the groups, similar to the ques-
tionnaires used in palliative research.41 In addition, the 
use of supportive care services should be measured be-
cause this may influence survivors΄  IPs.
The current study included a large and heterogeneous 
sample of survivors of various cancer types, but there were 
relatively many survivors with favorable prognoses, and 
a lack of common cancer types such as breast and lung 
cancer. Thus, despite our high response rate (71%), the 
findings of the current study may not be fully generaliz-
able to other cancer survivor populations. Furthermore, 
although our survival analyses demonstrated longitudinal 
associations, we could not confirm the causal relationship 
between IPs and HRQOL using a cross-sectional survey. 
Longitudinal surveys are needed to confirm the long-
term benefit of optimistic perceptions of illness and prog-
nosis. It also should be noted that our groups were created 
based on quartile cutoff values of the BIPQ scores, which 
are clinically arbitrary and are not validated using specific 
questionnaires for optimistic, realistic, or pessimistic IPs. 
Future studies are needed to confirm these IPs groups in 
other cancer survivor populations.
Future Directions
Although we acknowledge that the current study had 
limitations with regard to its design and the availability 
of data, and that further research is needed, we believe 
that its results provide valuable new insights into the 
importance of IPs among cancer survivors in relation to 
HRQOL and survival. The classification of survivors into 
groups based on IPs relative to their prognosis is a novel 
way with which to assess the impact of having threaten-
ing IPs on health outcomes, in contrast to a body of lit-
erature focusing on linear relationships between IPs and 
outcomes.2‒10 In a previous trial in which survivorship 
care plans were found to provide accurate and honest di-
agnostic and prognostic information, they induced more 
threatening IPs among cancer survivors.11‒13 Because the 
results of the current study indicate that holding realistic 
or pessimistic IPs may be associated with lower HRQOL 
and survival, we may need to be careful when provid-
ing information to survivors, such as diagnostic or prog-
nostic information. However, further research regarding 
this topic is warranted. Therefore, future interventions 
that include diagnostic or prognostic information should 
include an assessment of the potential harmful effects 
through more threatening IPs. Furthermore, rather than 
assuming that we need to encourage survivors with pes-
simistic IPs to be more optimistic, we believe it is impor-
tant to understand why these individuals have pessimistic 
or threatening IPs. It is possible that their perceptions are 
a much more inclusive reflection of their state of health 
than a set of objective measures comprises.36
Survivors with IPs that are relatively optimistic with 
respect to their prognosis appear to have the most favorable 
health outcomes, whereas those with pessimistic IPs rela-
tive to their prognosis have the worst outcomes compared 
with those with realistic IPs. Hence, IPs may be important 
predictors of health outcomes independent of prognosis. 
Figure 1. Kaplan-Meier survival curves for survivors with 
optimistic, realistic, and pessimistic illness perceptions (IPs). 
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We need to acknowledge the pessimistic or threatening 
IPs among cancer survivors and provide support that is 
appropriate for this group to improve their outcomes.
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